However, this particular vaccine is not approved for use in the United States, and while it may boost immunity, no randomised controlled studies so far have proven its actual clinical effectiveness. The review looks at serogroup C conjugate meningococcal vaccines (MCC) and their possible role in helping to prevent bacterial meningitis and its complications. Such vaccines are already widely used in Great Britain, Canada and Spain.
“The studies in our review showed that MCC vaccine was highly immunogenic in infants after two and three doses, in toddlers after one and two doses, and in older age groups after one dose,” said lead researcher Dr. Lucieni Oliveira Conterno of the Marilia Medical School in São Paulo, Brazil. The review authors analysed information from 17 randomised clinical studies on antibody responses to MCC vaccines and observational studies.
The MCC vaccine protects against only one “type” of meningitis, called serogroup C. The vaccine has not been approved by the Food and Drug Administration. MPLS (meningococcal polysaccharide) vaccines, by contrast, are approved and already used in the United States and elsewhere. “In general, higher titers were generated after MCC than after MPLS vaccines,” Conterno said.
“The review concluded that if one were to use conjugated vaccine in an attempt to protect against serogroup C in infants, it would likely be effective,” said Julia A. McMillan M.D., a professor of paediatrics at Johns Hopkins University School of Medicine. “There is, however, no FDA-approved conjugated vaccine in the U.S. that contains antigen against serogroup C alone.”
“This review can improve the confidence of using MCC vaccine, based on good evidence about immunogenicity and indirect evidence of clinical efficacy,” suggested Conterno.
MEDICA.de; Source: Health Behaviour News Service